Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME

被引：0
|
作者：
Inzucchi, S. E. [1 ]
Khunti, K. [2 ]
Fitchett, D. H. [3 ]
Wanner, C. [4 ]
Mattheus, M. [5 ]
George, J. T. [6 ]
Ofstad, A. P. [7 ]
Zinman, B. [8 ]
机构：
[1] Yale Sch Med, Sect Endocrinol, New Haven, CT USA
[2] Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Leicester, Leics, England
[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[4] Wurzburg Univ Clin, Div Nephrol, Wurzburg, Germany
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[7] Boehringer Ingelheim Norway KS, Asker, Norway
[8] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Toronto, ON, Canada
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2020年 / 104卷
关键词：
Sodium glucose co-transport inhibitor 2; Cardioprotection; Heart failure;
D O I：
10.1016/j.metabol.2019.12.071
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Zinman, Bernard
    Fitchett, David
    Wanner, Christoph
    Ferrannini, Ele
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Johansen, Odd Erik
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    DIABETES CARE, 2018, 41 (02) : 356 - 363
  • [42] Effect of empagliflozin on anthropometry and indices of visceral and total adiposity in patients with type 2 diabetes and high cardiovascular risk: EMPA-REG OUTCOME
    Neeland, L. J.
    McGuire, D. K.
    Fernandez, C. S.
    Mattheus, M.
    Woerle, H. -J.
    Johansen, O.
    Fitchett, D.
    DIABETOLOGIA, 2016, 59 : S348 - S348
  • [43] The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
    Neeland, Ian J.
    Eliasson, Bjorn
    Kasai, Takatoshi
    Marx, Nikolaus
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Zwiener, Isabella
    Wojeck, Brian S.
    Yaggi, Henry K.
    Johansen, Odd Erik
    DIABETES CARE, 2020, 43 (12) : 3007 - 3015
  • [44] Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
    Kaku, Kohei
    Lee, Jisoo
    Mattheus, Michaela
    Kaspers, Stefan
    George, Jyothis
    Woerle, Hans-Juergen
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    Lamkanfi, F.
    CIRCULATION JOURNAL, 2017, 81 (02) : 227 - +
  • [45] Empagliflozin and Progression of Kidney Disease in Patients at High Renal Risk: Slope Analyses from EMPA-REG OUTCOME®
    Wanner, Christoph
    Heerspink, Hiddo J. L.
    Koitka-Weber, Audrey
    Mattheus, Michaela
    Von Eynatten, Maximilian
    Groop, Per-Henrik
    DIABETES, 2017, 66 : A314 - A314
  • [46] EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL
    Wanner, Christoph
    Levin, Adeera
    Perkovic, Vlado
    Koitka-Weber, Audrey
    Mattheus, Michaela
    von Eynatten, Maximilian
    Wheeler, David
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [47] Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial
    Yaggi, H. K.
    Eliasson, B.
    Kasai, T.
    Marx, N.
    Zinman, B.
    Inzucchi, S. E.
    Wanner, C.
    Zwiener, I
    Wojeck, B.
    Neeland, I
    Johansen, O.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2883 - 2883
  • [48] Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME
    Vaduganathan, Muthiah
    Sattar, Naveed
    Fitchett, David H.
    Ofstad, Anne Pernille
    Brueckmann, Martina
    George, Jyothis T.
    Verma, Subodh
    Mattheus, Michaela
    Wanner, Christoph
    Inzucchi, Silvio E.
    Zinman, Bernard
    Butler, Javed
    CIRCULATION, 2020, 142
  • [49] Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial
    Kuo, Shihchen
    Ye, Wen
    Duong, Justin
    Herman, William H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 141 : 181 - 189
  • [50] Obstructive Sleep Apnoe and Cardiovascular, Heart Failure and Mortality Outcomes with Empagliflozin Versus Placebo in the EMPA-REG Outcome®Trial
    Yaggi, H. K.
    Eliasson, B.
    Kasai, T.
    Marx, N.
    Zinman, B.
    Inzucchi, S. S. E.
    Wanner, C.
    Zwiener, I.
    Wojeck, B.
    Neeland, I. J.
    Johansen, O.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345